KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa

R. Jain, V. V. Beckett, M. W. Konstan, F. J. Accurso, J. L. Burns, N. Mayer-Hamblett, Carlos Milla, D. R. VanDevanter, J. F. Chmiel

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Background: Chronic Pseudomonas aeruginosa (Pa) airways infection, exuberant local inflammation, and progressive lung function loss are hallmarks of cystic fibrosis (CF). KB001-A is an anti-PcrV PEGylated monoclonal antibody fragment to the Type III secretion system of Pa. This 16-week study evaluated KB001-A associated effect on time-to-need for antibiotics for worsening respiratory signs and symptoms, as well as safety, and treatment-associated changes in symptom scores, inflammatory markers, and spirometry. Methods: This was a randomized, double-blind, placebo-controlled, repeat-dose study in CF subjects with Pa. Intravenous 10 mg/kg KB001-A or placebo infusions were administered at baseline and weeks 2, 4, 8, and 16, with a 4-week follow-up. Sputum inflammatory markers were assessed in a sub-study. Time-to-need for antibiotics was compared between groups by Kaplan Meier analysis and Cox proportional hazards modeling adjusting for randomization strata. Results: Of 182 subjects, 169 received at least one infusion of KB001-A (n = 83) or placebo (n = 86). KB001-A was generally safe and well-tolerated as compared to placebo, with no significant emergent adverse effects other than one serious adverse event of elevated hepatic enzymes of unclear etiology. Time to need for antibiotics did not differ between groups (HR: 1.00; 95% CI: 0.69, 1.45, p = 0.995). A 3.2 increase in ppFEV 1 from placebo favoring KB001-A was observed at week 16 (95% CI: 1.12, 5.30, p = 0.003). Mean changes from baseline in log 10 sputum neutrophil elastase (NE) had a non-significant decrease (− 0.27, 95% CI: − 0.58,0.04, p = 0.084) while IL-8 concentrations at week 16 were significantly lower (− 0.27, 95% CI: − 0.55,0.00, p = 0.048) among KB001-A subjects (n = 16) relative to placebo (n = 13). Conclusions: KB001-A was safe and well-tolerated and associated with a modest FEV 1 benefit and reduction in select sputum inflammatory markers (IL-8). KB001-A was not associated with an increased time to need for antibiotics. The lack of efficacy seen with KB001-A may be due, in part, to the low levels of the type III secretion proteins previously reported in sputum of CF patients chronically infected with Pa.

Original languageEnglish (US)
Pages (from-to)484-491
Number of pages8
JournalJournal of Cystic Fibrosis
Volume17
Issue number4
DOIs
StatePublished - Jul 2018

Keywords

  • Anti-inflammatory
  • Cystic fibrosis
  • Pseudomonas aeruginosa infection
  • Type III secretion system

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa'. Together they form a unique fingerprint.

  • Cite this

    Jain, R., Beckett, V. V., Konstan, M. W., Accurso, F. J., Burns, J. L., Mayer-Hamblett, N., Milla, C., VanDevanter, D. R., & Chmiel, J. F. (2018). KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis, 17(4), 484-491. https://doi.org/10.1016/j.jcf.2017.12.006